About Leucid Bio
Leucid Bio is a company based in London (United Kingdom) founded in 2014 by John Maher.. Leucid Bio has raised $21.54 million across 3 funding rounds from investors including Epidarex Capital, 2Invest AG and Vulpes. The company has 10 employees as of June 30, 2022. Leucid Bio offers products and services including Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms. Leucid Bio operates in a competitive market with competitors including Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter London, United Kingdom
- Employees 10 as on 30 Jun, 2022
- Founders John Maher
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Leucid Bio Ltd
- Date of Incorporation 27 Nov, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$21.54 M (USD)
in 3 rounds
-
Latest Funding Round
$16.19 M (USD), Series A
Jun 24, 2021
-
Investors
Epidarex Capital
& 4 more
-
Employee Count
10
as on Jun 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Leucid Bio
Leucid Bio offers a comprehensive portfolio of products and services, including Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Redesigned CAR structure enhances T-cell potency for cancer treatment.
Autologous CAR T-cell product for head and neck cancer patients.
Targets NKG2D ligands in solid tumours and haematological malignancies.
Rapid, scalable method using blood draws for cell therapy.
Unlock access to complete
Funding Insights of Leucid Bio
Leucid Bio has successfully raised a total of $21.54M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $16.19 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $16.2M
-
First Round
First Round
(04 Jul 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series A - Leucid Bio | Valuation | Epidarex Capital , Vulpes Investment Management | |
| Aug, 2019 | Amount | Seed - Leucid Bio | Valuation |
investors |
|
| Jul, 2017 | Amount | Seed - Leucid Bio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Leucid Bio
Leucid Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Epidarex Capital, 2Invest AG and Vulpes. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investments in biotechnology, life sciences, and IT are managed by 2Invest AG.
|
Founded Year | Domain | Location | |
|
Early-stage tech and offline investments are managed across sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Leucid Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Leucid Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Leucid Bio Comparisons
Competitors of Leucid Bio
Leucid Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Leucid Bio
Frequently Asked Questions about Leucid Bio
When was Leucid Bio founded?
Leucid Bio was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is Leucid Bio located?
Leucid Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Leucid Bio?
Artin Moussavi is the current CEO of Leucid Bio.
Is Leucid Bio a funded company?
Leucid Bio is a funded company, having raised a total of $21.54M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.92M, raised on Jul 04, 2017.
How many employees does Leucid Bio have?
As of Jun 30, 2022, the latest employee count at Leucid Bio is 10.
What does Leucid Bio do?
Developer of therapeutics for the treatment of cancers. The company has CAR T-cell therapies which reprogram patients immune cells to recognize and destroy the cancer cells. The drug candidates include LEU-001 and LEU-005 for solid tumors, LEU-004, and LEU-006 for hematological malignancies.
Who are the top competitors of Leucid Bio?
Leucid Bio's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Leucid Bio offer?
Leucid Bio offers Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms.
Who are Leucid Bio's investors?
Leucid Bio has 5 investors. Key investors include Epidarex Capital, 2Invest AG, Vulpes, Future Fund, and Sofinnova Partners.
What is Leucid Bio's valuation?
The valuation of Leucid Bio is $44.36M as of Jun 2021.